134 related articles for article (PubMed ID: 21681778)
1. RhoGDIα suppresses growth and survival of prostate cancer cells.
Zhu Y; Tummala R; Liu C; Nadiminty N; Lou W; Evans CP; Zhou Q; Gao AC
Prostate; 2012 Mar; 72(4):392-8. PubMed ID: 21681778
[TBL] [Abstract][Full Text] [Related]
2. RhoGDIα downregulates androgen receptor signaling in prostate cancer cells.
Zhu Y; Liu C; Tummala R; Nadiminty N; Lou W; Gao AC
Prostate; 2013 Nov; 73(15):1614-22. PubMed ID: 23922223
[TBL] [Abstract][Full Text] [Related]
3. Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α.
Barone I; Brusco L; Gu G; Selever J; Beyer A; Covington KR; Tsimelzon A; Wang T; Hilsenbeck SG; Chamness GC; Andò S; Fuqua SA
J Natl Cancer Inst; 2011 Apr; 103(7):538-52. PubMed ID: 21447808
[TBL] [Abstract][Full Text] [Related]
4. NF-kappaB2/p52 enhances androgen-independent growth of human LNCaP cells via protection from apoptotic cell death and cell cycle arrest induced by androgen-deprivation.
Nadiminty N; Chun JY; Lou W; Lin X; Gao AC
Prostate; 2008 Dec; 68(16):1725-33. PubMed ID: 18781579
[TBL] [Abstract][Full Text] [Related]
5. The prostatic environment suppresses growth of androgen-independent prostate cancer xenografts: an effect influenced by testosterone.
Jennbacken K; Gustavsson H; Tesan T; Horn M; Vallbo C; Welén K; Damber JE
Prostate; 2009 Aug; 69(11):1164-75. PubMed ID: 19399749
[TBL] [Abstract][Full Text] [Related]
6. Enhanced sensitivity to androgen withdrawal due to overexpression of interleukin-6 in androgen-dependent human prostate cancer LNCaP cells.
Terakawa T; Miyake H; Furukawa J; Ettinger SL; Gleave ME; Fujisawa M
Br J Cancer; 2009 Nov; 101(10):1731-9. PubMed ID: 19844233
[TBL] [Abstract][Full Text] [Related]
7. Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts.
Locke JA; Nelson CC; Adomat HH; Hendy SC; Gleave ME; Guns ES
J Steroid Biochem Mol Biol; 2009 Jul; 115(3-5):126-36. PubMed ID: 19442514
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin derivative (smsDX) targets cellular metabolism in prostate cancer cells after androgen deprivation therapy.
Yan L; Xing Z; Guo Z; Fang Z; Jiao W; Guo X; Xu Z; Fang Z; Liu Z
PLoS One; 2013; 8(2):e55790. PubMed ID: 23409045
[TBL] [Abstract][Full Text] [Related]
9. The hippo pathway effector YAP regulates motility, invasion, and castration-resistant growth of prostate cancer cells.
Zhang L; Yang S; Chen X; Stauffer S; Yu F; Lele SM; Fu K; Datta K; Palermo N; Chen Y; Dong J
Mol Cell Biol; 2015 Apr; 35(8):1350-62. PubMed ID: 25645929
[TBL] [Abstract][Full Text] [Related]
10. Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc.
Chuu CP; Kokontis JM; Hiipakka RA; Fukuchi J; Lin HP; Lin CY; Huo C; Su LC; Liao S
Cancer Sci; 2011 Nov; 102(11):2022-8. PubMed ID: 21781227
[TBL] [Abstract][Full Text] [Related]
11. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
[TBL] [Abstract][Full Text] [Related]
12. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
Thomas C; Wafa LA; Lamoureux F; Cheng H; Fazli L; Gleave ME; Rennie PS
Prostate; 2012 Jun; 72(8):875-85. PubMed ID: 22072572
[TBL] [Abstract][Full Text] [Related]
13. Ubiquitous mitochondrial creatine kinase is overexpressed in the conditioned medium and the extract of LNCaP lineaged androgen independent cell lines and facilitates prostate cancer progression.
Pang B; Zhang H; Wang J; Chen WZ; Li SH; Shi QG; Liang RX; Xie BX; Wu RQ; Qian XL; Yu L; Li QM; Huang CF; Zhou JG
Prostate; 2009 Aug; 69(11):1176-87. PubMed ID: 19415690
[TBL] [Abstract][Full Text] [Related]
14. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.
Locke JA; Guns ES; Lubik AA; Adomat HH; Hendy SC; Wood CA; Ettinger SL; Gleave ME; Nelson CC
Cancer Res; 2008 Aug; 68(15):6407-15. PubMed ID: 18676866
[TBL] [Abstract][Full Text] [Related]
15. TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling.
Ibuki N; Ghaffari M; Pandey M; Iu I; Fazli L; Kashiwagi M; Tojo H; Nakanishi O; Gleave ME; Cox ME
Int J Cancer; 2013 Oct; 133(8):1955-66. PubMed ID: 23564295
[TBL] [Abstract][Full Text] [Related]
16. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-6 regulates androgen synthesis in prostate cancer cells.
Chun JY; Nadiminty N; Dutt S; Lou W; Yang JC; Kung HJ; Evans CP; Gao AC
Clin Cancer Res; 2009 Aug; 15(15):4815-22. PubMed ID: 19638459
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of calcium/calmodulin-dependent protein kinase kinase 2 by androgen deprivation induces castration-resistant prostate cancer.
Shima T; Mizokami A; Miyagi T; Kawai K; Izumi K; Kumaki M; Ofude M; Zhang J; Keller ET; Namiki M
Prostate; 2012 Dec; 72(16):1789-801. PubMed ID: 22549914
[TBL] [Abstract][Full Text] [Related]
19. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.
Berenguer C; Boudouresque F; Dussert C; Daniel L; Muracciole X; Grino M; Rossi D; Mabrouk K; Figarella-Branger D; Martin PM; Ouafik L
Oncogene; 2008 Jan; 27(4):506-18. PubMed ID: 17637748
[TBL] [Abstract][Full Text] [Related]
20. Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity.
Siu SW; Lau KW; Tam PC; Shiu SY
Prostate; 2002 Jul; 52(2):106-22. PubMed ID: 12111702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]